Get startedLog in
    Picture of Opus Genetics logo

    IRD — Opus Genetics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousSmall CapMomentum Trap
    All News

    Brief: Opus Genetics Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint For Phentolamine Ophthalmic Solution

    Picture of Opus Genetics logoOpus Genetics
    26/06/2025 11:57
    June 26 (Reuters) - Opus Genetics Inc IRD.O:

OPUS GENETICS ANNOUNCES VEGA-3 PHASE 3 TRIAL MET ITS PRIMARY ENDPOINT FOR PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% FOR THE TREATMENT OF PRESBYOPIA

OPUS GENETICS INC - VEGA-3 TRIAL MEETS KEY SECONDARY EFFICACY ENDPOINTS

OPUS GENETICS INC - TO FILE FDA APPLICATION IN SECOND HALF OF 2025

Source text: ID:nGNX9H4BBM

Further company coverage: IRD.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Opus Genetics

    See all news